Breast Cancer

Genasense Enhances Activity of Chemotherapy in Mouse Model

Published in Gene Therapy Weekly, August 10th, 2000

Genta Inc. (GNTA), Lexington, Massachusetts, announced publication of study results with Genasense, an antisense drug used in combination with doxorubicin, a standard therapy for breast cancer.

In the study, immune-deficient mice were transplanted with human breast cancer and then treated with Genasense, either alone or with doxorubicin. Whereas the individual agents showed only modest activity when used alone, the two-drug combination yielded highly synergistic antitumor activity.

The authors noted that most previous studies of Genasense, which targets the Bcl-2 protein, have tested tumor cells that were known to express high levels of Bcl-2. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-08-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry